JACQUELINE BORZEKOFSKI: Open Payments
NPI 1629848049 · LINCOLN, NE. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$210 in 11 payments from 10 companies in 2025. Trend: 2023 $0 · 2024 $50 · 2025 $210
Food & beverage: $210
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 2 | $48 |
| Novo Nordisk Inc | 1 | $30 |
| PFIZER INC. | 1 | $22 |
| Lilly USA, LLC | 1 | $20 |
| Axsome Therapeutics, Inc. | 1 | $17 |
| Organon LLC | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
| Actelion Pharmaceuticals US, Inc. | 1 | $14 |
| AstraZeneca Pharmaceuticals LP | 1 | $14 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $14 |
Products named: REXULTI, Ozempic, VYNDAMAX, JARDIANCE, Symbravo, NEXPLANON, Korlym, OPSUMIT.
Industry payments across NE — which companies pay providers there.
